GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (FRA:XP0) » Definitions » Shiller PE Ratio

Xenon Pharmaceuticals (FRA:XP0) Shiller PE Ratio : (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Xenon Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Xenon Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals Shiller PE Ratio Chart

Xenon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xenon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xenon Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Xenon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Shiller PE Ratio falls into.



Xenon Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xenon Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Xenon Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.57/125.4675*125.4675
=-0.570

Current CPI (Mar. 2024) = 125.4675.

Xenon Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.000 99.473 0.000
201409 0.205 99.394 0.259
201412 0.539 98.367 0.687
201503 -0.591 99.789 -0.743
201506 -0.062 100.500 -0.077
201509 -0.241 100.421 -0.301
201512 -0.248 99.947 -0.311
201603 -0.207 101.054 -0.257
201606 -0.374 102.002 -0.460
201609 -0.454 101.765 -0.560
201612 -0.303 101.449 -0.375
201703 -0.402 102.634 -0.491
201706 -0.365 103.029 -0.444
201709 -0.361 103.345 -0.438
201712 -0.380 103.345 -0.461
201803 -0.170 105.004 -0.203
201806 -0.385 105.557 -0.458
201809 -0.540 105.636 -0.641
201812 -0.255 105.399 -0.304
201903 -0.372 106.979 -0.436
201906 -0.327 107.690 -0.381
201909 -0.300 107.611 -0.350
201912 -0.369 107.769 -0.430
202003 -0.199 107.927 -0.231
202006 -0.004 108.401 -0.005
202009 -0.212 108.164 -0.246
202012 -0.279 108.559 -0.322
202103 -0.353 110.298 -0.402
202106 -0.423 111.720 -0.475
202109 -0.306 112.905 -0.340
202112 -0.425 113.774 -0.469
202203 -0.318 117.646 -0.339
202206 -0.520 120.806 -0.540
202209 -0.576 120.648 -0.599
202212 -0.538 120.964 -0.558
202303 -0.588 122.702 -0.601
202306 -0.665 124.203 -0.672
202309 -0.684 125.230 -0.685
202312 -0.587 125.468 -0.587
202403 -0.570 125.468 -0.570

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xenon Pharmaceuticals  (FRA:XP0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Xenon Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals (FRA:XP0) Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Xenon Pharmaceuticals (FRA:XP0) Headlines

No Headlines